Therapy of chronic hepatitis Delta virus infection remains an unmet need. An estimate 20-40 million individuals are infected worldwide, mostly with rapidly evolving liver disease. To date, only IFN-based therapy is recommended for hepatitis Delta; response rates are unsatisfactory and, in addition, many patients are intolerant or ineligible to IFN. In recent years innovative approachs have been in development, which targets virus entry into hepatocytes; inhibition of the host enzyme farnesyltransferase, which leads to inhibition of complete virion formation and release; blockade of HBsAg secretion, which inhibits virus release; IFN Lamda, which causes fewer adverse effects than IFN alfa. Clinical trials are ongoing with encouraging preliminary results.
Treatment of chronic hepatitis due to Hepatitis B with Delta virus coinfection
Brancaccio, Giuseppina;Gaeta, Giovanni B
Writing – Original Draft Preparation
2019
Abstract
Therapy of chronic hepatitis Delta virus infection remains an unmet need. An estimate 20-40 million individuals are infected worldwide, mostly with rapidly evolving liver disease. To date, only IFN-based therapy is recommended for hepatitis Delta; response rates are unsatisfactory and, in addition, many patients are intolerant or ineligible to IFN. In recent years innovative approachs have been in development, which targets virus entry into hepatocytes; inhibition of the host enzyme farnesyltransferase, which leads to inhibition of complete virion formation and release; blockade of HBsAg secretion, which inhibits virus release; IFN Lamda, which causes fewer adverse effects than IFN alfa. Clinical trials are ongoing with encouraging preliminary results.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
